In 2020, the global antibody drug market will exceed $150 billion, and the five major target "cornucopia" will be released

In the past two months, following the disclosure of the financial reports of various pharmaceutical giants, the annual global sales of best-selling drugs ushered in the most comprehensive inventory.

The global antibody market has exceeded 150 billion U.

Bamlanivimab and REGEN-COV, which debuted in the 2020 earnings report, performed well.

Table 1: Antibody drugs with global sales of over 100 million U.

Note: The exchange rate is converted into 1 Euro = 1.

Five major targets "cornucopia" totaled 91 billion U.

According to the statistics of antibody drugs in the financial reports of major pharmaceutical companies, the top five sales targets of antibody drugs in 2020 are: TNFα, PD-1/PD-L1, VEGF/VEGFR, HER2 and CD20, the top five targets The scale of the antibody market of Dian reaches 91 billion U.

Figure 1: The proportion of antibody sales in the world's top ten targets

Among the world's top ten target antibodies, 9 companies with 3 or more varieties include Roche, Amgen, Johnson & Johnson, Novartis, Tanabe Mitsubishi, Merck, Eli Lilly, Pfizer, Daiichi Sankyo, etc.

Roche widened the gap with the second-ranked company by a large proportion.

Figure 2: Companies with 3 or more target varieties in the top ten sales

The five major target antibody domestic wars are raging, and the target king translocates

In foreign countries, Xiu Mei Le successfully held its position as the world's drug king for the eighth consecutive year, and helped the entire TNFα target to stay on top of antibody drugs.

In China, the target PD-1/PD-L1 is another style.

Figure 3: Sales of the five major targets in 2020H1 in China's public medical institutions

Source: Mi Nei.

The antibody drug market is currently the largest category in the global biopharmaceutical market.

The steadily increasing sales figures brought about by commercial value also promotes R&D companies to conduct more in-depth research on popular targets.
Only the persistent research on innovation and unpopular targets will usher in year after year in financial reporting.
New faces appearing in.
Traveling against the current, if you do not advance, you will retreat.
The situation of antibody targets is completely different at home and abroad, which is a vigilance for domestic companies and also a business opportunity.

Source: Corporate financial reports, Mynet’s multinational listed company sales database, Mynet’s global drug R&D database

Original title: In 2020, the global antibody drug market will exceed $150 billion, and the five major target "cornucopia" will be released.
Does the domestic PD-1/PD-L1 turn over the TNFα car?